Modern Setup Host Windows 10
Kroger Feedback

Blog

Live Blog | SDPA Summer Conference 2016

LIVE BLOG | Treating Advanced Basal Cell Carcinoma Through Hedgehog Pathway Inhibition

In this live blog from the SDPA Annual Summer Dermatology Conference in Austin, TX, Dr. Snehal Amin, presented a product theater for Genentech called, “Treating Advanced Basal Cell Carcinoma Through Hedgehog Pathway Inhibition.

Highlights:

  • Erivedge (vismodegib) is the first oral FDA-approved for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation.
  • Erivedge was shown to be effective in patients with locally advanced and metastatic basal cell carcinoma.
  • Erivedge works by inhibiting the Hedgehog pathway.
  • Erivedge is the first FDA-approved oral medication of its kind.

More:

Dr. Amin described Erivedge (vismodegib), an oral medication for the treatment of adults with metastatic basal cell carcinoma or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation.

Dr. Amin said that Erivedge was shown to be effective in ERIVANCE, a phase II trial of patients with locally advanced or metastatic basal cell carcinoma. Patients received 150mg of Erivedge once a day, and 43% of patients with locally advanced basal cell carcinoma responded to treatment – 21% achieving a complete response and 22% achieving a partial response. Among patients with metastatic basal cell carcinoma, 30% achieved a partial response. The median duration of response was approximately 8 months for both groups of patients. The most common side effects were mild or moderate muscle spasms and alopecia.

Dr. Amin noted that Erivedge has a black box warning because of the potential to cause embryo-fetal death or severe birth defects when administered to pregnant women.

Dr. Amin explained that Erivedge works by inhibiting the Hedgehog pathway, a known driver of basal cell carcinoma. He explained that Erivedge is the first FDA-approved oral medication of its kind. Dr. Amin shared that 4,200 patients thus far have been treated with Erivedge.




Our Sponsors